Haleon plc (NYSE:HLN) Position Lowered by Point72 Asset Management L.P.

Point72 Asset Management L.P. lessened its stake in Haleon plc (NYSE:HLN - Free Report) by 66.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 312,829 shares of the company's stock after selling 620,371 shares during the quarter. Point72 Asset Management L.P.'s holdings in Haleon were worth $2,584,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Clearbridge Investments LLC grew its position in Haleon by 44.6% during the first quarter. Clearbridge Investments LLC now owns 38,446,978 shares of the company's stock valued at $326,415,000 after acquiring an additional 11,865,076 shares during the period. Wellington Management Group LLP increased its position in Haleon by 164.6% during the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company's stock worth $111,454,000 after purchasing an additional 8,423,475 shares in the last quarter. Sculptor Capital LP increased its position in Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company's stock worth $73,407,000 after purchasing an additional 3,592,000 shares in the last quarter. Douglas Lane & Associates LLC lifted its position in Haleon by 1.6% during the second quarter. Douglas Lane & Associates LLC now owns 8,533,768 shares of the company's stock valued at $70,489,000 after buying an additional 131,892 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Haleon by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company's stock worth $62,549,000 after buying an additional 196,843 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Down 1.3 %

Haleon stock traded down $0.14 during midday trading on Thursday, hitting $10.40. 5,558,145 shares of the stock were exchanged, compared to its average volume of 5,073,532. Haleon plc has a 1 year low of $7.70 and a 1 year high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm has a market cap of $47.49 billion, a P/E ratio of 34.47, a P/E/G ratio of 3.12 and a beta of 0.26. The company has a 50 day moving average price of $10.04 and a two-hundred day moving average price of $8.99.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The business had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. During the same quarter last year, the firm posted $0.08 EPS. On average, sell-side analysts predict that Haleon plc will post 0.47 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were paid a dividend of $0.0514 per share. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend was Friday, August 16th. Haleon's dividend payout ratio (DPR) is currently 33.33%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HLN. UBS Group upgraded shares of Haleon to a "strong-buy" rating in a report on Tuesday. Morgan Stanley boosted their price objective on Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a research note on Friday, September 20th. The Goldman Sachs Group lowered Haleon from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 6th. Finally, Berenberg Bank began coverage on Haleon in a research report on Tuesday, August 6th. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.